Boehringer Ingelheim Inks Up-to-$7.4B+ Cancer Drug Collaboration with Sino Biopharmaceutical

T2Covered by 1 source · first reported by Fierce Biotech / Fierce Healthcare / MedCity / GEN at 05 Nov, 21:20 UTC

The latest collaboration will encompass six biologic preclinical programs. Five programs focus on treatments originating with a wholly owned SBP Group subsidiary, LaNova Medicines. The sixth comes from another SBP Group subsidiary, Beijing Tide Pharmaceutical. The post Boehringer Ingelheim Inks…

science

Sources

• T2Boehringer Ingelheim Inks Up-to-$7.4B+ Cancer Drug Collaboration with Sino BiopharmaceuticalFierce Biotech / Fierce Healthcare / MedCity / GEN05 Nov, 21:20